ESSA Pharma (EPIX) announces that its Securityholders have approved the acquisition of all of the issued and outstanding common shares of the Company by XenoTherapeutics Inc., a non-profit biotechnology company, by way of a statutory plan of arrangement at the special meeting of Securityholders held today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPIX:
- ESSA Pharma Faces Class Action Lawsuit in California
- ESSA Pharma Receives Court Approval for Acquisition
- Essa Pharma provides update on combination agreement with Xeno
- ESSA Pharma Amends Agreement with XenoTherapeutics, Adjusts Shareholder Terms
- Essa Pharma amends business combination agreement with XenoTherapeutics